| Stereochemistry | ACHIRAL |
| Molecular Formula | C36H37N7O4 |
| Molecular Weight | 631.7235 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C=C(NC(=O)C2=CC(NC(=O)C3=CC=C(\C=C\C4=CC5=C(C=CC=C5)N=C4)C=C3)=CN2C)C=C1C(=O)NCCN6CCOCC6
InChI
InChIKey=OEKXCVYZBVOWBR-BQYQJAHWSA-N
InChI=1S/C36H37N7O4/c1-41-24-30(20-32(41)35(45)37-13-14-43-15-17-47-18-16-43)40-36(46)33-21-29(23-42(33)2)39-34(44)27-11-9-25(10-12-27)7-8-26-19-28-5-3-4-6-31(28)38-22-26/h3-12,19-24H,13-18H2,1-2H3,(H,37,45)(H,39,44)(H,40,46)/b8-7+
| Molecular Formula | C36H37N7O4 |
| Molecular Weight | 631.7235 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 1 |
| Optical Activity | NONE |
MGB-BP 3 is an antibacterial agent being developed by MGB Biopharma. This drug is now in phase II clinical trial to assess the safety, tolerability, and efficacy of incremental doses in patients with Clostridium difficile-associated diarrhea. In addition, this drug is studied for the treatment of Gram-positive infections; and skin and soft tissue infections.
